Mineralys Therapeutics

Aldosterone synthase inhibitor for hypertension/CKD/OSA

MLYS · Nasdaq · United States

Share price · MLYS

$13.78-12.83 (-48.21%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.4M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MLYS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026-14.5%

    Nothing announced by MLYS that day or the session before.

  2. 30 Oct 2026-14.4%
  3. 8 Sep 2026+10.3%

    Nothing announced by MLYS that day or the session before.

  4. 2 Sep 2026+13.6%

    Nothing announced by MLYS that day or the session before.

  5. 3 Jun 2026-13.1%
  6. 13 May 2026-8.2%
  7. 1 May 2026+9.8%
  8. 15 Apr 2026+11.3%

    Nothing announced by MLYS that day or the session before.

  9. 31 Mar 2026+15.2%

    Nothing announced by MLYS that day or the session before.

  10. 20 Mar 2026+3.4%

Share of unusual movement by asset

For each asset, the share of MLYS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Lorundrostat
events and moves
1615%
Other company news (earnings, financing, releases naming no asset)—53%
Sessions with no dated event—32%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Aldosterone synthase (CYP11B2)Small molecule
HypertensionChronic Kidney Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

22 December 2026FDA action dateLorundrostatPDUFA date 22 December 2026 for lorundrostat
US, FDA · Mineralys Therapeutics · Source ↗

Recent

9 March 2026Filing acceptedLorundrostatFDA accepts lorundrostat NDA
US, FDA · Mineralys Therapeutics · Source ↗
9 March 2026Topline resultLorundrostatPhase 2 Explore-OSA topline: apnea-hypopnea index primary endpoint not met
17 June 2025Topline resultLorundrostatPhase 2 Explore-CKD (NCT06150924) of lorundrostat met its primary endpoint
Mineralys Therapeutics · Source ↗
10 March 2025Topline resultLorundrostatLaunch-HTN Phase 3 topline results

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$23M$101M+ $523M short-term inv.$57M-$43M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$221M$138M+ $523M short-term inv.$241M-$33M operating cash flowreport ↗
2026-Q1—$24M$113M+ $533M short-term inv.$39M-$39M operating cash flowreport ↗
2025-Q3—$31M$218M+ $376M short-term inv.$37M-$29M operating cash flowreport ↗
2025-Q2—$38M$102M+ $223M short-term inv.$43M-$30M operating cash flowreport ↗
2025-Q1—$38M$165M+ $178M short-term inv.$42M-$45M operating cash flowreport ↗
2024-Q3—$54M$97M+ $166M short-term inv.$56M-$50M operating cash flowreport ↗
2024-Q2—$39M$68M+ $243M short-term inv.$41M-$30M operating cash flowreport ↗
2024-Q1—$31M$90M+ $248M short-term inv.$32M-$19M operating cash flowreport ↗
2023-Q3—$23M$86M+ $167M short-term inv.$23M-$19M operating cash flowreport ↗
2023-Q2—$12M$101M+ $160M short-term inv.$12M-$20M operating cash flowreport ↗
2023-Q1—$12M$138M+ $132M short-term inv.$13M-$13M operating cash flowreport ↗
2022-Q3—$6.1M$49M$6.7M-$7.0M operating cash flowreport ↗
2022-Q2—$5.6M$128M$6.5M-$5.5M operating cash flowreport ↗
2022-Q1—$6.8M$16M$7.6M-$6.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$132M$173M+ $484M short-term inv.$39M-$142M operating cash flowreport ↗

Mineralys Therapeutics reported full-year 2025 financial results with revenue not disclosed. R&D spend was $132.01M, down 21.7% YoY. Cash and equivalents were $172.92M, while total cash, cash equivalents and investments were $656.6M as of December 31, 2025. The company reported a net loss of $154.65M for the year and a fourth-quarter net loss of $32.2M.

Management stated that current cash, cash equivalents and investments are expected to fund planned clinical trials, regulatory activities, and corporate operations into 2028. The FDA accepted the NDA for lorundrostat in hypertension, with a PDUFA target date of December 22, 2026. Topline data from the Explore-OSA Phase 2 trial showed no clinically meaningful difference from placebo on the primary AHI endpoint after four weeks, though blood pressure reductions were observed; the Transform-HTN open-label extension trial is ongoing.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$169M$114M+ $84M short-term inv.$44M-$166M operating cash flowreport ↗
2023-FY—$70M$49M+ $187M short-term inv.$18M-$81M operating cash flowreport ↗
2022-FY—$26M$88M+ $22M short-term inv.$7.5M-$29M operating cash flowreport ↗
2021-FY——$11M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($8.8M), 57 sales ($27.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-19COATS LONNEL · directorAward / grant12,400——Form 4
2026-10-19Peterson Kristine · directorAward / grant12,400——Form 4
2026-10-19COATS LONNEL · directorAward / grant (derivative)16,600——Form 4
2026-10-19Peterson Kristine · directorAward / grant (derivative)16,600——Form 4
2026-09-30Congleton Jon · director, Chief Executive OfficerOpen-market sale75,000$25.46$1.9MForm 4
2026-09-22Slingsby Brian Taylor · directorOpen-market sale104,320$28.81$3.0MForm 4
2026-09-21Warren Eric · Chief Commercial OfficerOption exercise7,438$13.24$98KForm 4
2026-09-21Warren Eric · Chief Commercial OfficerOpen-market sale7,438$28.12$209KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 213 reporting institutions held 90.9M shares ($2.4B, 110.1% of shares outstanding).

#InstitutionSharesValue
1Catalys Pacific, LLC7,903,838$214.1M
2RA CAPITAL MANAGEMENT, L.P.7,692,750$208.4M
3SAMSARA BIOCAPITAL, LLC5,871,018$159.0M
4FMR LLC4,861,104$131.7M
5BlackRock, Inc.4,481,582$121.4M
6WELLINGTON MANAGEMENT GROUP LLP3,359,068$91.0M
7STATE STREET CORP2,935,940$79.5M
8Caligan Partners LP2,772,654$75.1M
9VANGUARD CAPITAL MANAGEMENT LLC2,454,363$66.5M
10Laurion Capital Management LP2,232,040$60.5M
11ORBIMED ADVISORS LLC2,052,900$55.6M
12Point72 Asset Management, L.P.1,911,433$51.8M
13FRANKLIN RESOURCES INC1,784,662$48.3M
14ANDERA PARTNERS1,591,917$43.1M
15SR One Capital Management, LP1,563,966$42.4M